Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rocket Pharmaceuticals Inc (NQ: RCKT )

18.54 +0.94 (+5.34%)
Streaming Delayed Price Updated: 1:51 PM EDT, Sep 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Rocket Pharmaceuticals Inc

< Previous 1 2 3 4 Next >
Health Care Company Rocket Pharmaceuticals Announces Acquisition of Renovacor
Rocket Pharmaceuticals (NASDAQ:RCKT) has announced an acquisition of Renovacor (AMEX:RCOR) that is expected to be completed in Q1 of 2023. 
Via Benzinga
Why Is Renovacor (RCOR) Stock Up 18% Today?
Renovacor (RCOR) stock is gaining on Tuesday after announcing that Rocket Pharmaceuticals (RCKT) is acquiring it in an all-stock deal. 
Via InvestorPlace
Rocket Pharmaceuticals Buys Renovacor, Strengthening Position In Gene Therapies For Heart Diseases
Via Benzinga
Rocket Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
On Thursday, Rocket Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 88 to 94. 
Via Investor's Business Daily
Raymond James Maintains Outperform Rating for Rocket Pharmaceuticals: Here's What You Need To Know
  Raymond James has decided to maintain its Outperform rating of Rocket Pharmaceuticals (NASDAQ:RCKT) and raise its price target from $22.00 to $24.00. Shares of Rocket Pharmaceuticals are trading up... 
Via Benzinga
Rocket Pharmaceuticals: Q2 Earnings Insights
  Rocket Pharmaceuticals (NASDAQ:RCKT) reported its Q2 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Analyst Ratings for Rocket Pharmaceuticals
Rocket Pharmaceuticals (NASDAQ:RCKT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
4 Analysts Have This to Say About Rocket Pharmaceuticals
Within the last quarter, Rocket Pharmaceuticals (NASDAQ:RCKT) has observed the following analyst ratings: 
Via Benzinga
Rocket Pharma's Gene Therapy Shows 100% Overall Survival In Immune Deficiency Disorder
Via Benzinga
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX... 
Via Benzinga
Why Jim Cramer Says This Stock Is 'Definitely A Buy'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is with Tellurian Inc. (NYSE: TELL). 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low. 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis. 
Via Benzinga
Raymond James Initiates Coverage On This Stock With Bullish Pitch On Gene Therapies
Raymond James initiated coverage on Rocket Pharmaceuticals Inc (NASDAQ: RCKT) with an Outperform rating with a $22 price target based on the positive view of RP-L102 and RP-L201 gene therapy programs... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022
Via Benzinga
Analyst Ratings for Rocket Pharmaceuticals
Over the past 3 months, 4 analysts have published their opinion on Rocket Pharmaceuticals (NASDAQ:RCKT) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Executives Buy Around $64M Of 3 Stocks
US stock futures traded higher this morning, with the Dow futures adding more than 200 points this morning. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
5 Beaten Down Biotech Stocks That Could Bounce Big In 2022
Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout... 
Via Benzinga
Rocket Pharma To Test Lower Dose Of Gene Therapy In Genetic Disorder Trial
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has announced updated data from the Phase 1 trial evaluating a single intravenous infusion of RP-A501, an investigational... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 236 companies hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 242 companies hit new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Tricida (NASDAQ:TCDA) shares rose... 
Via Benzinga
70 Biggest Movers From Yesterday
Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The... 
Via Benzinga
The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novavax Shares React to Reports Of Manufacturing Issues With Its COVID-19... 
Via Benzinga
Rocket Pharma Posts Interim Data From Immunodeficiency Disorder Gene Therapy Trial
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has announced interim data updates from seven patients from the RP-L201 Phase 1/2 trial for Leukocyte Adhesion Deficiency... 
Via Benzinga
FDA Lifts Clinical Hold On Rocket Pharma's X-Linked Inherited Disorder Trial
The 
Via Benzinga
Exposures Product Safety
74 Biggest Movers From Yesterday
Gainers Bit Digital, Inc. (NASDAQ: BTBT) shares jumped 109.7% to close at $8.87 on Monday after the company announced it entered into a second strategic co-mining agreement with... 
Via Benzinga
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.